Valion Bio raises $7.737 million via Series B/C preferred and warrants
Valion Bio entered a private placement letter agreement with 3i to issue Series B and Series C preferred shares with accompanying warrants for $7.737 million.
Valion Bio entered into a private placement Letter Agreement with 3i to issue Series B and Series C preferred shares, plus accompanying warrants, for $7.737 million. Of that amount, $6.137 million will be used to satisfy overdue true-up payments, while $100,000 will cover 3i’s legal fees and $1.5 million remains outstanding in the source section.